WIT Pharma
All insights
Regulatory11 November 2026 · 6 min read

Compulsory licences as a market access factor: what autumn 2026 has shown

Within six weeks the courts granted compulsory licences for cabotegravir and dolutegravir and refused them for risdiplam and grazoprevir + elbasvir, while the Supreme Court clarified how a shortage is proven. We look at which circumstances prove decisive and how patent status ties in with inclusion in the reimbursement lists.

Between late September and early November 2026 the Russian courts handed down several decisions on compulsory licences for medicines - and they point in different directions. Licences for cabotegravir and dolutegravir were granted; licences for risdiplam and the grazoprevir + elbasvir combination were refused. For right holders and for companies planning generic launches, this is a reason to look at which circumstances the courts treat as material. This review is based on published court acts and media reports; some cases were heard in closed session, and in some the reasoning has not yet been published.

The framework: three routes

The Civil Code provides three mechanisms. The first is Article 1362(1): a court grants a licence where the invention is not used or is insufficiently used by the right holder, resulting in insufficient supply of the product on the market, and the right holder has refused to conclude a licence agreement. The second is Article 1362(2): a licence for the holder of a dependent invention that constitutes an important technical advance and offers substantial economic advantages. The third is Article 1360: the decision is taken by the Government in cases of extreme necessity relating, among other things, to the protection of citizens' life and health; this is how permissions to use the semaglutide patents were issued in 2024-2025.

In Ruling No. 13-P of 12 March 2026 (on complaints by Sanofi Russia and Vertex Pharmaceuticals) the Constitutional Court found Article 1362(1) consistent with the Constitution and set a reference point: the purpose of a compulsory licence is to saturate the market with products whose properties are equivalent to the original, and its terms must be proportionate to that purpose.

Cabotegravir: registered but not supplied

On 20 October 2026 the Moscow Region Commercial Court (case No. A41-84432/2026) granted the claim of Biokhimik (Promomed group) against ViiV Healthcare and Shionogi: a non-exclusive licence under the patents insofar as they relate to cabotegravir, covering Russia, for the full term of the patents. The royalty is 1.75% of actual revenue from sales of the products. The central fact of the case: the originator product is registered in Russia but has never been released into civil circulation; the Ministry of Health took part as a third party. The judgment has not entered into force and may be appealed.

Dolutegravir: a licence despite a localised originator

On 3 November 2026 the Ninth Commercial Court of Appeal (case No. A40-150885/2024) overturned the July refusal by the Moscow Commercial Court and granted the same company's claim in full: a licence under Eurasian patent No. 014162 insofar as it relates to dolutegravir, covering Russia, for the full term of the patent (until July 2029). The claimant sought royalties of 1.7% of sales income.

The difference from cabotegravir is fundamental: the originator product is manufactured in Russia at the Servier Rus site and is being supplied. The court of first instance saw no shortage risk and found it unproven that the claimant uses its own inventions in its product. The claim rests on the claimant's patents for methods of producing and purifying the substance - the dependent-invention construct. The reasoning of the appeal ruling had not been published as of 11 November, so it is premature to judge which arguments proved decisive. The ruling may be challenged in cassation.

Where the courts refuse

In the same weeks Geropharm received two refusals. On risdiplam (respondents - Roche and PTC Therapeutics) the Moscow Commercial Court refused on 3 August, and the Ninth Commercial Court of Appeal upheld the decision on 20 October; the originator product is registered and supplied. On grazoprevir and the grazoprevir + elbasvir combination (respondent - MSD) the Moscow Commercial Court refused on 22 October; according to Vademecum, the claimant's own generic had not been registered at the time of the decision. Both cases were heard in closed session and the reasoning is unavailable, so a comparison with the cases where licences were granted is possible only on external features.

The Supreme Court: how a shortage is proven

Ruling No. 305-ES26-12482 of the Supreme Court's Judicial Chamber for Economic Disputes (full text issued on 2 October 2026, case No. A41-75087/2025) concerns a veterinary product but matters for human medicines as well. The Chamber set aside the ruling of the Intellectual Property Court and upheld the first-instance and appeal acts granting the licences, treating the termination and restriction of originator supplies since 2022 as a sufficient ground. The facts of insufficient use are established by the first-instance and appeal courts, and the range of admissible evidence is wider than a regulator's opinion.

What follows

For right holders. The most exposed position is a product that is registered but in practice not supplied, or supplied with interruptions: registration without release into circulation offers no protection. What has to be proven consists of verifiable facts - batches released into circulation, participation in tenders, stock levels - and these are worth documenting in advance. A separate link is the response to a licence offer: refusal to contract is an element of Article 1362, so an offer left unanswered works against the right holder. The dolutegravir case suggests that localisation and stable supply may not rule out a licence on the dependent-invention ground, but until the reasoning is published this is an observation, not a conclusion.

For generic manufacturers. The courts assess readiness rather than intent: a registered product, production capability and the licence terms offered.

For market access planning. A licence in itself does not open the way to reimbursement. On 10 November the Ministry of Health commission refused to add cabotegravir and rilpivirine to the VED list because the applicant's products had not yet been released into civil circulation (see our review of the session). Patent status, the status of court acts and actual release into circulation are three different dates, and a forecast of the competitive picture in tenders needs to track each of them.

Sources

Civil Code of the Russian Federation, Articles 1360 and 1362; Constitutional Court Ruling No. 13-P of 12 March 2026 (pravo.gov.ru, No. 0001202603130001); Ruling No. 305-ES26-12482 of the Judicial Chamber for Economic Disputes of the Supreme Court of 2 October 2026 (vsrf.ru); the commercial courts' case database (cases No. A41-84432/2026, No. A40-150885/2024, No. A41-75087/2025); naecz.ru (25 October 2026); Interfax (9 November 2026); Vademecum (10 September, 3 and 9 November 2026); Kommersant, Pravo.ru, Advokatskaya Gazeta, GxP News, Pharmvestnik (October - November 2026).

This material is for information purposes only and does not constitute legal advice. Decisions on the inclusion of medicines in reimbursement lists are made by the authorised state bodies.

Questions on market access in Russia and the EAEU? Talk to the WIT Pharma team. Full texts of the documents mentioned are available in the key regulations section.